Back

Myocarditis with prevalent arrhythmic manifestation: clinical features and outcome during long-term follow up

17 March 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Moderated ePosters 4: Understanding the substrate for ventricular arrhythmias Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Doctor Gino Grifoni

University Hospital of Pisa, Pisa (Italy)

7 More presentations in this session

Presentation thumbnail
Validation of a novel software application for non-invasive localisation of premature ventricular complexes (PVC) and ventricular tachycardia (VT) to guide catheter ablation
Doctor Z. Vali (Leicester, GB)
Abstract
Presentation thumbnail
Retrograde coronary venous and intracoronary ethanol injection for ventricular ectopic ablation
Professor P. Lambiase (London, GB)
Presentation thumbnail
Prognostic significance of ventricular arrhythmias in titin-related dilated cardiomyopathy for the outcome of catheter ablation - Results from a multicenter experience
Doctor M. Ebert (Dresden, DE)
Abstract Slides
Presentation thumbnail
Electroanatomic and histological right ventricular outflow tract alterations in patients with Brugada syndrome
Doctor M. Nesti (Pisa, IT)
Abstract Slides
Presentation thumbnail
Septal late gadolinium enhancement and conduction delay on ECG in nonischemic dilated cardiomyopathy
Ms M. Becker (Amsterdam, NL)
Abstract Slides

Access the full session

Session thumbnail
Moderated ePosters 4: Understanding the substrate for ventricular arrhythmias

The Event

Event poster

EHRA 2019

17 March - 19 March 2019
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources